Briefing
A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy
Hong Kong phase 3 trial that randomized patients with residual plasma EBV DNA after radiotherapy to adjuvant chemotherapy versus observation; the published result (Chan et al., JCO 2018, PMID 29989858) showed no RFS improvement (5-year RFS 49.3% vs 54.7%; HR 1.09, P=0.75).
- Design: Phase 3 · Completed